Inflammatory mediators alter interleukin-17 receptor, interleukin-12 and -23 expression in human osteoarthritic and rheumatoid arthritis synovial fibroblasts: Immunomodulation by vasoactive intestinal peptide

NeuroImmunoModulation

Volumn 20, Issue 5, 2013, Pages 274-284

  Carrión, Mar ^a   Pérez García, Selene ^a   Jimeno, Rebeca ^a   Juarranz, Yasmina ^a   González Álvaro, Isidoro ^b   Pablos, José Luis ^c   Gutiérrez Cañas, Irene ^a   Gomariz, Rosa P ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Instituto de Investigación Hospital 12 de Octubre ^*  (Spain)

Author keywords

Interleukin 12; Interleukin 17 receptor; Interleukin 23; Rheumatic diseases; Synovial fibroblasts; Vasoactive intestinal peptide

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 23P19; LIPOPOLYSACCHARIDE; MESSENGER RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MICROENVIRONMENT; NEUROMODULATION; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; STIMULATION; SUPERNATANT; SYNOVIOCYTE; TH1 CELL; TH17 CELL; UPREGULATION;

ANALYSIS OF VARIANCE; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYTOKINES; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; LIGANDS; LIPOPOLYSACCHARIDES; OSTEOARTHRITIS; POLYDEOXYRIBONUCLEOTIDES; RECEPTORS, INTERLEUKIN-17; RNA, MESSENGER; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84882290791     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159000350892116049     Document Type: Article

References (49)

1. Firenstein GS: Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-361.
2. Scanzello CR, Goldring SR: The role of synovitis in osteoarthritis pathogenesis. Bone 2012; 51: 249-257.
3. Korhonen R, Moilanen E: Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2009; 104: 276-284.
4. Neumann E, Lefevre S, Zimmermann B, Gay S, Muller-Ladner U: Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med 2010; 16: 458-468.
5. Miossec P, Kolls J: Targeting IL-17 and Th17 cells in chronic inflammation. Nat Rev Drug Discov 2012; 11: 763-776.
6. Ge D, You Z: Expression of interleukin-17RC protein in normal human tissues. Int Arch Med 2008; 1: 19.
7. van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, Dolhain RJ, Lubberts E: Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011; 63: 73-83.
8. Vignali DA, Kuchroo VK: IL-12 family cytokines: immunological playmakers. Nat Immunol 2012; 13: 722-728.
9. Rong C, Hu W, Wu FR, Cao XJ, Chen FH: Interleukin-23 as a potential therapeutic target for rheumatoid arthritis. Mol Cell Biochem 2012; 361: 243-248.
10. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid model of Crohn's disease. Gastroenterology 2003; 124: 961-971.
11. Li H, Mei Y, Wang Y, Xu L: Vasoactive intestinal peptide suppressed experimental autoimmune encephalomyelitis by inhibiting Thelper 1 responses. J Clin Immunol 2006; 26: 430-437.
12. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP, Baum BJ: Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006; 65: 195-200.
13. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Waschek JA, Kort S: Moderate pulmonary arterial hypertension in the male mice lacking the vasoactive intestinal peptide gene. Circulation 2007; 115: 1260-1268.
14. Jimeno R, Gomariz RP, Gutierrez-Canas I, Martinez C, Juarranz Y, Leceta J: New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 2010; 88: 734-745.
15. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7: 563-568.
16. Juarranz MG, Santiago B, Torroba M, Gutierrez-Canas I, Palao G, Galindo M, Abad C, Martinez C, Leceta J, Pablos JL, Gomariz RP: Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology 2004; 43: 416-422.
17. Gutierrez-Canas I, Juarranz Y, Santiago B, Arranz A, Martinez C, Galindo M, Paya M, Gomariz RP, Pablos JL: VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology 2006; 45: 527-532.
18. Arranz A, Gutierrez-Canas I, Carrion M, Juarranz Y, Pablos JL, Martinez C, Gomariz RP: VIP reverses the expression profiling of TLR4-stimulated signalling pathway in rheumatoid arthritis synovial fibroblasts. Mol Immunol 2008; 45: 3065-3073.
19. Juarranz Y, Gutierrez-Canas I, Santiago B, Carrion M, Pablos JL, Gomariz RP: Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 2008; 58: 1086-1095.
20. Juarranz Y, Gutierrez-Canas I, Arranz A, Martinez C, Abad C, Leceta J, Pablos JL, Gomariz RP: VIP decreases TLR4 expression induced by LPS and TNFá treatment in human synovial fibroblasts. Ann NY Acad Sci 2006; 1070: 359-364.
21. Gutierrez-Canas I, Juarranz Y, Santiago B, Martinez C, Gomariz RP, Pablos JL, Leceta J: Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun 2008; 22: 312-317.
22. Aletaha D, Neogi T, Silman AJ, et al: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-2581.
23. Carrion M, Juarranz Y, Perez-Garcia S, Jimeno R, Pablos JL, Gomariz RP, Gutierrez-Canas I: RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. Arthritis Rheum 2011; 63: 1626-1636.
24. Goriely S, Molle C, Nguyen M, Albarani V, Haddou NO, Lin R, De Wit D, Flamand V, Willems F, Goldman M: Interferon regulatory factor 3 is involved in Toll-like receptor 4 (TLR4)-and TLR3-induced IL-12p35 gene activation. Blood 2006; 107: 1078-1084.
25. Garrett S, Fitzgerald MC, Sullivan KE: LPS and poly I:C induce chromatin modifications at a novel upstream region of the IL-23 p19 promoter. Inflammation 2008; 31: 235-246.
26. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ: Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54: 1122-1131.
27. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA: IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008; 454: 350-352.
28. Zrioual S, Toh ML, Tournadre A, Zhou Y, Cazalis MA, Pachot A, Miossec V, Miossec P: IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol 2008; 180: 655-663.
29. Kehlen A, Thiele K, Riemann D, Langner J: Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol 2002; 127: 539-546.
30. Hwang SY, Kim HY: Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cells 2005; 19: 180-184.
31. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P: Genome-wide comparison between IL-17A-and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol 2009; 182: 3112-3120.
32. Toussirot E, Roudier J: Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. Joint Bone Spine 2007; 74: 418-426.
33. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D: RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005; 52: 2656-2665.
34. Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, Schreurs BW, van den Berg WB, Radstake TR: Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 2006; 176: 7021-7027.
35. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B: Tenascin-C is an endogenous activator of Tolllike receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15: 774-780.
36. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, van der Meer JW, Netea MG, van den Berg WB: Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007; 56: 2957-2967.
37. Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, van den Bersselaar LA, Koenders MI, van den Berg WB: Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production. Arthritis Rheum 2008; 58: 3753-3764.
38. Toh ML, Gonzales G, Koenders MI, Tournadre A, Boyle D, Lubberts E, Zhou Y, Firestein GS, van den Berg WB, Miossec P: Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS One 2010; 5:e13416.
39. Pope RM, Shaharara S: Possible roles of IL-12 family cytokines in rheumatoid arthritis. Nat Rev Rheumatol 2012; 9: 252-256.
40. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
41. Kim W, Min S, Cho M, Youn J, Min J, Lee S, Park S, Cho C, Kim H: The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis(RA). Clin Exp Immunol 2000; 119: 175-181.
42. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ: Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-1957.
43. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR: Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008; 58: 875-887.
44. Nistala K, Adams S, Cambrook H, Ursu S, Olivito B, de Jager W, Evans JG, Cimaz R, Bajaj-Elliott M, Wedderburn LR: Th17 plasticity in human autoimmune arthritis is driven by the inflammatory microenvironment. Proc Natl Acad Sci USA 2010; 107: 14751-14756.
45. Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, Park SH, Lee SH, Kim HY: Upregulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase, NF-κB and p38 MAPKdependent signalling pathways. Rheumatology 2007; 46: 57-64.
46. Brentano F, Ospelt C, Stanczyk J, Gay RE, Gay S, Kyburz D: Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 143-150.
47. Goldberg M, Nadiv O, Luknar-Gabor N, Agar G, Beer Y, Katz Y: Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009; 46: 1854-1859.
48. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, van den Berg WB, Radstake TR: The expression of toll-like receptors 3 and 7 in rheumatoid synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005; 52: 2313-2322.
49. Pierer M, Wagner U, Rossol M, Ibrahim S: Toll-like receptor 4 is involved in inflammatory and joint destructive pathways in collagen-induced arthritis in DBA1J mice. PLoS One 2011; 6:e23539.